ADHD-associated dopamine transporter, latrophilin and neurofibromin share a dopamine-related locomotor signature in Drosophila

Molecular Psychiatry

Volumn 21, Issue 4, 2016, Pages 565-573

  Van Der Voet, M ^a,b   Harich, B ^a,b   Franke, B ^a,b   Schenck, A ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; LATROPHILIN; METHYLPHENIDATE; NEUROFIBROMIN; UNCLASSIFIED DRUG; ALPHA-LATROTOXIN RECEPTOR; DOPAMINE; RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DROSOPHILA; ENDOPHENOTYPE; GENETIC BACKGROUND; HYPERACTIVITY; LOCOMOTION; MALE; MONOGENIC DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SLEEP PATTERN; SLEEP TIME; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DROSOPHILA; MALE; METHYLPHENIDATE; NEUROFIBROMIN 1; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

EID: 84929232769     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.55     Document Type: Article

References (82)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edn American Psychiatric Association: Arlington, VA: 2000.
2. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-Analysis. Br J Psychiatry 2009; 194: 204-211.
3. Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CHD, Ramos-Quiroga JA, et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 2012; 17: 960-987.
4. Yoon SYR, Jain U, Shapiro C. Sleep in attention-deficit/hyperactivity disorder in children and adults: past, present, and future. Sleep Med Rev 2012; 16: 371-388.
5. Van Veen MM, Kooij JJS, Boonstra AM, Gordijn MCM, Van Someren EJW. Delayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia. Biol Psychiatry 2010; 67: 1091-1096.
6. Baird AL, Coogan AN, Siddiqui A, Donev RM, Thome J. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Molecular Psychiatry 2012; 17: 988-995.
7. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005; 57: 1313-1323.
8. Acosta MT, Arcos-Burgos M, Muenke M. Attention deficit/hyperactivity disorder. (ADHD): complex phenotype, simple genotype?. Gene Med 2004; 6: 1-15.
9. Zhang L, Chang S, Li Z, Zhang K, Du Y, Ott J, et al. ADHDgene: a genetic database for attention deficit hyperactivity disorder. Nucleic Acids Res 2012; 40: D1003-D1009.
10. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a metaanalytic review. Hum Genet 2009; 126: 51-90.
11. Li D, Sham PC, Owen MJ, He L. Meta-Analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder. (ADHD). Hum Mol Genet 2006; 15: 2276-2284.
12. Bralten J, Franke B, Waldman I, Rommelse N, Hartman C, Asherson P, et al. Candidate genetic pathways for attention-deficit/hyperactivity disorder. (ADHD). show association to hyperactive/impulsive symptoms in children with ADHD. J Am Acad Child Adolesc Psychiatry 2013; 52: 1204-1212.
13. Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, et al. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry 2010; 15: 1053-1066.
14. Mautner V-F, Kluwe L, Thakker SD, Leark RA. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002; 44: 164-170.
15. Millan MJ. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 2013; 68: 2-82.
16. Barton B, North K. Social skills of children with neurofibromatosis type 1. Dev Med Child Neurol 2004; 46: 553-563.
17. Pride NA, Payne JM, North KN. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 2012; 37: 590-600.
18. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.
19. Wilson MC. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2000; 24: 51-57.
20. Swallow JG, Carter PA, Garland T. Artificial selection for increased wheel-running behavior in house mice. Behav Genet 1998; 28: 227-237.
21. Tsai CF, Lin MT. Locomotor hyperactivity in hypertensive rats. Pharmacology 1988; 36: 27-34.
22. Lange M, Norton W, Coolen M, Chaminade M, Merker S, Proft F, et al. The ADHDsusceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. Mol Psychiatry 2012; 17: 946-954.
23. Wallis D, Hill DS, Mendez IA, Abbott LC, Finnell RH, Wellman PJ, et al. Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res 2012; 1463: 85-92.
24. Diggs-Andrews KA, Tokuda K, Izumi Y, Zorumski CF, Wozniak DF, Gutmann DH. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol 2013; 73: 309-315.
25. Brown JA, Emnett RJ, White CR, Yuede CM, Conyers SB, O'Malley KL, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 2010; 19: 4515-4528.
26. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry 2009; 43: 101-108.
27. Matthews KA, Kaufman TC, Gelbart WM. Research resources for Drosophila: the expanding universe. Nat Rev Genet 2005; 6: 179-193.
28. Van Der Voet M, Nijhof B, Oortveld MAW, Schenck A. Drosophila models of early onset cognitive disorders and their clinical applications. Neurosci Biobehav Rev 2014; 46: 326-342.
29. Lichtneckert R, Reichert H. Insights into the urbilaterian brain: conserved genetic patterning mechanisms in insect and vertebrate brain development. Heredity. (Edinb). 2005; 94: 465-477.
30. Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet 2005; 6: 9-23.
31. O?Kane CJ. Drosophila as a model organism for the study of neuropsychiatric disorders. In: Molecular and functional models of neuropsychiatry. Curr Topic Behav Neurosci 2011; 7, p 37-60.
32. Van Alphen B, Van Swinderen B. Drosophila strategies to study psychiatric disorders. Brain Res Bull 2013; 92: 1-11.
33. Schenck A, Bardoni B, Langmann C, Harden N, Mandel J-L, Giangrande A. CYFIP/ Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 2003; 38: 887-898.
34. Kramer JM, Kochinke K, Oortveld MAW, Marks H, Kramer D, De Jong EK, et al. Epigenetic regulation of learning and memory by Drosophila EHMT/G9a. PLoS Biol 2011; 9: e1000569.
35. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008; 4: 256-263.
36. McBride SMJ, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005; 45: 753-764.
37. Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol 2014; 50: 297-302.
38. Kume K, Kume S, Park SK, Hirsh J, Jackson FR. Dopamine is a regulator of arousal in the fruit fly. J Neurosci 2005; 25: 7377-7384.
39. Van Swinderen B, Brembs B. Attention-like deficit and hyperactivity in a Drosophila memory mutant. J Neurosci 2010; 30: 1003-1014.
40. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993; 118: 401-415.
41. Dietzl G, Chen D, Schnorrer F, Su K-C, Barinova Y, Fellner M, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 2007; 448: 151-156.
42. Ni J-Q, Liu L-P, Binari R, Hardy R, Shim H-S, Cavallaro A, et al. A Drosophila resource of transgenic RNAi lines for neurogenetics. Genetics 2009; 182: 1089-1100.
43. Green EW, Fedele G, Giorgini F, Kyriacou CP. A Drosophila RNAi collection is subject to dominant phenotypic effects. Nat Meth 2014; 11: 222-223.
44. Poelmans G, Pauls DL, Buitelaar JK, Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 2011; 168: 365-377.
45. Hinney A, Scherag A, Jarick I, Albayrak Ö, Pütter C, Pechlivanis S, et al. Genomewide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 888-897.
46. Stergiakouli E, Hamshere M, Holmans P, Langley K, Zaharieva I, deCODE Genetics, et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry 2012; 169: 186-194.
47. Yang L, Neale BM, Liu L, Lee SH, Wray NR, Ji N, et al. Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: genome-wide association study of both common and rare variants. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 419-430.
48. Sánchez-Mora C, Ramos-Quiroga JA, Bosch R, Corrales M, Garcia-Martínez I, Nogueira M, et al. Case-control genome-wide association study of persistent attention-deficit hyperactivity disorder identifies FBXO33 as a novel susceptibility gene for the disorder. Neuropsychopharmacology 2015; 40: 915-926.
49. Marygold SJ, Leyland PC, Seal RL, Goodman JL, Thurmond J, Strelets VB, et al. FlyBase: improvements to the bibliography. Nucleic Acids Res 2013; 41: D751-D757.
50. Vilella AJ, Severin J, Ureta-Vidal A, Heng L, Durbin R, Birney E. EnsemblCompara GeneTrees: Complete, duplication-Aware phylogenetic trees in vertebrates. Genome Res 2009; 19: 327-335.
51. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30: 2725-2729.
52. McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res 2013; 41: W597-W600.
53. Gilestro GF, Cirelli C. pySolo: a complete suite for sleep analysis in Drosophila. Bioinformatics 2009; 25: 1466-1467.
54. Miano S, Parisi P, Villa MP. The sleep phenotypes of attention deficit hyperactivity disorder: the role of arousal during sleep and implications for treatment. Med Hypotheses 2012; 79: 147-153.
55. Rosato E, Kyriacou CP. Analysis of locomotor activity rhythms in Drosophila. Nat Protoc 2006; 1: 559-568.
56. Chintapalli VR, Wang J, Dow JAT. Using FlyAtlas to identify better Drosophila melanogaster models of human disease. Nat Genet 2007; 39: 715-720.
57. Shang Y, Haynes P, Pírez N, Harrington KI, Guo F, Pollack J, et al. Imaging analysis of clock neurons reveals light buffers the wake-promoting effect of dopamine. Nat Neurosci 2011; 14: 889-895.
58. Mao Z, Davis RL. Eight different types of dopaminergic neurons innervate the Drosophila mushroom body neuropil: anatomical and physiological heterogeneity. Front Neural Circuits 2009; 3: 5.
59. Liu Q, Liu S, Kodama L, Driscoll MR, Wu MN. Two dopaminergic neurons signal to the dorsal fan-shaped body to promote wakefulness in Drosophila. Curr Biol 2012; 22: 2114-2123.
60. Ueno T, Tomita J, Tanimoto H, Endo K, Ito K, Kume S, et al. Identification of a dopamine pathway that regulates sleep and arousal in Drosophila. Nat Neurosci 2012; 15: 1516-1523.
61. Williams JA, Su HS, Bernards A, Field J, Sehgal A. A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 2001; 293: 2251-2256.
62. Chung BY, Kilman VL, Keath JR, Pitman JL, Allada R. The GABA(A). receptor RDL acts in peptidergic PDF neurons to promote sleep in Drosophila. Curr Biol 2009; 19: 386-390.
63. Gmeiner F, Kolodziejczyk A, Yoshii T, Rieger D, Nässel DR, Helfrich-Förster C. GABA. (B). receptors play an essential role in maintaining sleep during the second half of the night in Drosophila melanogaster. J Exp Biol 2013; 216: 3837-3843.
64. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B, et al. CDBE2010 study group The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155-162.
65. Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003; 42: 1415-1423.
66. Kaufmann D, Wiandt S, Veser J, Krone W. Increased melanogenesis in cultured epidermal melanocytes from patients with neurofibromatosis 1. (NF 1). Hum Genet 1991; 87: 144-150.
67. Volz TJ. Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Curr Neuropharmacol 2008; 6: 379-385.
68. Kumar S, Chen D, Sehgal A. Dopamine acts through Cryptochrome to promote acute arousal in Drosophila. Genes Dev 2012; 26: 1224-1234.
69. Vinayak P, Coupar J, Hughes SE, Fozdar P, Kilby J, Garren E, et al. Exquisite light sensitivity of Drosophila melanogaster cryptochrome. PLoS Genet 2013; 9: e1003615.
70. Vieira J, Jones AR, Danon A, Sakuma M, Hoang N, Robles D, et al. Human cryptochrome-1 confers light independent biological activity in transgenic Drosophila correlated with flavin radical stability. PLoS One 2012; 7: e31867.
71. Kooij JJS, Bijlenga D. The circadian rhythm in adult attention-deficit/hyperactivity disorder: current state of affairs. Expert Rev Neurother 2013; 13: 1107-1116.
72. Calipari ES, Ferris MJ, Salahpour A, CARON MG, Jones SR. Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun 2013; 4: 2720.
73. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N, et al. Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 2010; 30: 6048-6057.
74. Beaulieu J-M, Sotnikova TD, Gainetdinov RR, Caron MG. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem 2006; 281: 32072-32080.
75. O'Hara CM, Uhland-Smith A, O'Malley KL, Todd RD. Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther 1996; 277: 186-192.
76. Tissari AH, Atzori L, Galdieri MT. Inhibition of dopamine synthesis in striatal synaptosomes by lisuride: stereospecific reversal by. (-)-sulpiride. Naunyn Schmiedebergs Arch Pharmacol 1983; 322: 89-91.
77. Mayfield RD, Zahniser NR. Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol Pharmacol 2001; 59: 113-121.
78. Meiergerd SM, Patterson TA, Schenk JO. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 1993; 61: 764-767.
79. Bjornsti M-A. Cancer therapeutics in yeast. Cancer Cell 2002; 2: 267-273.
80. Wassmann K, Benezra R. Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 2001; 11: 83-90.
81. Pfau SJ, Amon A. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO reports 2012; 13: 515-527.
82. Gatto CL, Broadie K. Drosophila modeling of heritable neurodevelopmental disorders. Curr Opin Neurobiol 2011; 21: 834-841.